{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:49:02Z","timestamp":1782488942312,"version":"3.54.5"},"reference-count":43,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010526","name":"NHS Greater Glasgow and Clyde","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010526","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012095","name":"Scottish Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_PC_1717"],"award-info":[{"award-number":["MC_PC_1717"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,7,8]]},"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate psychotropic prescribing in the intellectual disabilities population over 10 years, and associated mental ill health diagnoses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Comparison of cross-sectional data in 2002\u20132004 (T1) and 2014 (T2). Longitudinal cohort study with detailed health assessments at T1 and record linkage to T2 prescribing data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>General community.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>1190 adults with intellectual disabilities in T1 compared with 3906 adults with intellectual disabilities in T2. 545\/1190 adults with intellectual disabilities in T1 were alive and their records linked to T2 prescribing data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Encashed regular and as-required psychotropic prescriptions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>50.7% (603\/1190) of adults in T1 and 48.2% (1881\/3906) in T2 were prescribed at least one psychotropic; antipsychotics: 24.5% (292\/1190) in T1 and 16.7% (653\/3906) in T2; antidepressants: 11.2% (133\/1190) in T1 and 19.1% (746\/3906) in T2. 21.2% (62\/292) prescribed antipsychotics in T1 had psychosis or bipolar disorder, 33.2% (97\/292) had no mental ill health or problem behaviours, 20.6% (60\/292) had problem behaviours but no psychosis or bipolar disorder. Psychotropics increased from 47.0% (256\/545) in T1 to 57.8% (315\/545) in T2 (p&lt;0.001): antipsychotics did not change (OR 1.18; 95% CI 0.87 to 1.60; p=0.280), there was an increase for antidepressants (OR 2.80; 95% CI 1.96 to 4.00; p&lt;0.001), hypnotics\/anxiolytics (OR 2.19; 95% CI 1.34 to 3.61; p=0.002), and antiepileptics (OR 1.40; 95% CI 1.06 to 1.84; p=0.017). Antipsychotic prescribing increased for people with problem behaviours in T1 (OR 6.45; 95% CI 4.41 to 9.45; p&lt;0.001), more so than for people with other mental ill health in T1 (OR 4.11; 95% CI 2.76 to 6.11; p&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite concerns about antipsychotic prescribing and guidelines recommending their withdrawal, it appears that while fewer antipsychotic prescriptions were initiated by T2 than in T1, people were not withdrawn from them once commenced. People with problem behaviours had increased prescribing. There was also a striking increase in antidepressant prescriptions. Adults with intellectual disabilities need frequent and careful medication reviews.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-036862","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:13Z","timestamp":1599782413000},"page":"e036862","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["Changes over a decade in psychotropic prescribing for people with intellectual disabilities: prospective cohort study"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6146-3477","authenticated-orcid":false,"given":"Angela","family":"Henderson","sequence":"first","affiliation":[{"name":"Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Mcskimming","sequence":"additional","affiliation":[{"name":"Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Kinnear","sequence":"additional","affiliation":[{"name":"Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"McCowan","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Saint Andrews, Saint Andrews, Fife, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair","family":"McIntosh","sequence":"additional","affiliation":[{"name":"Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Allan","sequence":"additional","affiliation":[{"name":"Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6054-7700","authenticated-orcid":false,"given":"Sally-Ann","family":"Cooper","sequence":"additional","affiliation":[{"name":"Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"2026062608014776000_10.9.e036862.1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.106.022483"},{"key":"2026062608014776000_10.9.e036862.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-007-0197-9"},{"key":"2026062608014776000_10.9.e036862.3","doi-asserted-by":"crossref","DOI":"10.1177\/0706743717727240","article-title":"Antipsychotic use with and without comorbid psychiatric diagnosis among adults with intellectual and developmental disabilities","volume":"63","author":"Lunsky","year":"2018","journal-title":"Can J Psychiatry"},{"key":"2026062608014776000_10.9.e036862.4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/0706743717727240","article-title":"Antipsychotic use with and without comorbid psychiatric diagnosis among adults with intellectual and developmental disabilities","volume":"63","author":"Lunsky","year":"2018","journal-title":"Can J Psychiatry"},{"key":"2026062608014776000_10.9.e036862.5","unstructured":"Glover G , Williams R . Prescribing of psychotropic drugs to people with learning disabilities and\/or autism by general practitioners in England. London: Public Health England, 2015."},{"key":"2026062608014776000_10.9.e036862.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2788.2010.01275.x"},{"key":"2026062608014776000_10.9.e036862.7","unstructured":"NICE . Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenge. London: NICE, 2015."},{"key":"2026062608014776000_10.9.e036862.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2010.05.005"},{"key":"2026062608014776000_10.9.e036862.9","doi-asserted-by":"publisher","DOI":"10.3109\/13668250.2013.778968"},{"key":"2026062608014776000_10.9.e036862.10","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h4326","article-title":"Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study","volume":"351","author":"Sheehan","year":"2015","journal-title":"BMJ"},{"key":"2026062608014776000_10.9.e036862.11","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","article-title":"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death","volume":"158","author":"Glassman","year":"2001","journal-title":"AJP"},{"key":"2026062608014776000_10.9.e036862.12","first-page":"162","article-title":"Medication-Induced tardive dyskinesia: a review and update","volume":"17","author":"Cornett","year":"2017","journal-title":"Ochsner J"},{"key":"2026062608014776000_10.9.e036862.13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry"},{"key":"2026062608014776000_10.9.e036862.14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.7850","article-title":"Antipsychotic treatment among youths with attention-deficit\/hyperactivity disorder","volume":"2","author":"Sultan","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026062608014776000_10.9.e036862.15","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jamapsychiatry.2015.0500","article-title":"Treatment of young people with antipsychotic medications in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"2026062608014776000_10.9.e036862.16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1089\/cap.2017.0077","article-title":"National patterns of commonly prescribed psychotropic medications to young people","volume":"28","author":"Sultan","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2026062608014776000_10.9.e036862.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g4323"},{"key":"2026062608014776000_10.9.e036862.18","unstructured":"NICE . Mental health problems in people with learning disabilities: prevention, assessment and management. London: NICE, 2016."},{"key":"2026062608014776000_10.9.e036862.19","unstructured":"Health Do . Transforming care: a national response to Winterbourne view Hospital: department of health review final report, 2012."},{"key":"2026062608014776000_10.9.e036862.20","unstructured":"Disability FoPoI . Psychotropic drug prescribing for people with intellectual disability, mental health problems and\/or behaviours that challenge: practice guidelines. London: The Royal College of Psychiatrists, 2016."},{"key":"2026062608014776000_10.9.e036862.21","unstructured":"England N . Stopping over medication of people with a learning disability, autism or both (STOMP, 2019. https:\/\/www.england.nhs.uk\/learning-disabilities\/improving-health\/stomp\/"},{"key":"2026062608014776000_10.9.e036862.22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/jir.12685","article-title":"Psychotropic medication use in adults with intellectual disability in Queensland, Australia, from 1999 to 2015: a cohort study","volume":"64","author":"Song","year":"2020","journal-title":"J Intellect Disabil Res"},{"key":"2026062608014776000_10.9.e036862.23","doi-asserted-by":"publisher","DOI":"10.1093\/jpepsy\/10.2.215"},{"key":"2026062608014776000_10.9.e036862.24","unstructured":"Organization WH . The ICD-10 classification of mental and behavioral disorders: diagnostic criteria for research. Geneva, Switzerland: World Health Organization, 1993."},{"key":"2026062608014776000_10.9.e036862.25","unstructured":"Association AP . Diagnostic and statistical manual of mental disorders. 4th edn. Washington DC, 2000."},{"key":"2026062608014776000_10.9.e036862.26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2788.2002.00403.x","article-title":"Diagnostic criteria for psychiatric disorders for use with adults with learning disabilities mental retardation)","volume":"46","author":"Szymanski","year":"2002","journal-title":"J Appl Res Intellect Disabil"},{"key":"2026062608014776000_10.9.e036862.27","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw060"},{"key":"2026062608014776000_10.9.e036862.28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4326"},{"key":"2026062608014776000_10.9.e036862.29","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/jar.12591","article-title":"Prevalence and patterns of antipsychotic use and their associations with mental health and problem behaviours among older adults with intellectual disabilities","volume":"32","author":"O'Dwyer","year":"2019","journal-title":"J Appl Res Intellect Disabil"},{"key":"2026062608014776000_10.9.e036862.30","doi-asserted-by":"publisher","DOI":"10.1002\/hup.470090405"},{"key":"2026062608014776000_10.9.e036862.31","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/jir.12359","article-title":"Prevalence of psychotropic medication use and association with challenging behaviour in adults with an intellectual disability. A total population study","volume":"61","author":"Bowring","year":"2017","journal-title":"J Intellect Disabil Res"},{"key":"2026062608014776000_10.9.e036862.32","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-019-2191-7","article-title":"Pharmacotherapy for mood and anxiety disorders in older people with intellectual disability in comparison with the general population","volume":"19","author":"Axmon","year":"2019","journal-title":"BMC Psychiatry"},{"key":"2026062608014776000_10.9.e036862.33","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp11X593848"},{"key":"2026062608014776000_10.9.e036862.34","first-page":"423","article-title":"Exploring potential explanations for the increase in antidepressant prescribing in Scotland using secondary analyses of routine data","volume":"56","author":"Munoz-Arroyo","year":"2006","journal-title":"Br J Gen Pract"},{"key":"2026062608014776000_10.9.e036862.35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38377.715799.F7"},{"key":"2026062608014776000_10.9.e036862.36","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp09X395076"},{"key":"2026062608014776000_10.9.e036862.37","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1365-2788.2000.00307.x","article-title":"Receipt of psychotropic medication by people with intellectual disability in residential settings","volume":"44 Pt 6","author":"Robertson","year":"2000","journal-title":"J Intellect Disabil Res"},{"key":"2026062608014776000_10.9.e036862.38","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2788.2003.00463.x"},{"key":"2026062608014776000_10.9.e036862.39","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-012-1617-6"},{"key":"2026062608014776000_10.9.e036862.40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2788.2006.00935.x"},{"key":"2026062608014776000_10.9.e036862.41","doi-asserted-by":"publisher","DOI":"10.3310\/hta21410"},{"key":"2026062608014776000_10.9.e036862.42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ridd.2015.11.017","article-title":"Adverse events and the relation with quality of life in adults with intellectual disability and challenging behaviour using psychotropic drugs","volume":"49-50","author":"Scheifes","year":"2016","journal-title":"Res Dev Disabil"},{"key":"2026062608014776000_10.9.e036862.43","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/jir.12391","article-title":"Prevalence, patterns and factors associated with psychotropic use in older adults with intellectual disabilities in Ireland","volume":"61","author":"O'Dwyer","year":"2017","journal-title":"J Intellect Disabil Res"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-036862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:07:36Z","timestamp":1782486456000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-036862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,10]]},"published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1136\/bmjopen-2020-036862"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-036862","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}